Rosa's Sharan A. Pagano, Senior Vice President of Scientific Alliances will present at the 7th Annual Shanghai Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA Shanghai 2016) on Friday, April 22, 2016. The conference focuses on the current industrial landscape and the global need to bring products to market faster. Ms. Pagano’s talk, entitled “Mechanistic Physiological PhysioPD™ Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach” will focus on the process of creating and conducting research using PhysioPD Platforms to drive scientific innovation in the pharmaceutical industry. PhysioPD Platforms are QSP models designed with multidisciplinary client team input. The PhysioPD research approach is planned to impact client decisions and has been successful across many therapeutic indications.(press release, slides)
Rosa & Co. LLC participated 2016 Roche QSP Methodology Workshop held on February 4 & 5th, 2016 in Basel, Switzerland. Dr. Christina Friedrich, Chief Engineer at Rosa, recently published an article on QSP model qualification, and participated in the workshop that brought together key opinion leaders from industry and academia to make a substantive contribution toward even broader implementation of QSP. The workshop capitalized on the group’s accumulated experience and applications to review and discuss evolving methodologies in the field. (press release)
Rosa & Co.’s Chief Engineer, Dr. Christina Friedrich published an article, “Model Qualification Method for Mechanistic Physiological QSP Models to Support Model-Informed Drug Development” in the CPT: Pharmacometrics & Systems Pharmacology Journal. QSP is being used increasingly by innovative R&D organizations as a powerful research approach that combines available data with scientific knowledge and engineering approaches to facilitate better understanding of biological systems, to improve decision-making, and to reduce risk and increase efficiency in drug discovery and development. Dr. Friedrich’s tutorial draws on years of experience to generate a rigorous, systematic, and broadly applicable Model Qualification Method (MQM) to ensure that QSP models are well-qualified and fit for their intended purposes. The MQM addresses questions of model relevance, scope, uncertainty, biological variability, and use of data, so that model-informed research can proceed with confidence. (Article) (press release)
Rosa & Co. LLC presented a poster at the 2015 Roche Pharma Research and Early Development (pRED) Symposium, held on November 2-3rd, 2015 in New York City. Rosa’s poster, entitled “Model qualification approaches for quantitative systems pharmacology (QSP) and mechanistic physiological models”, was presented by Dr. Christina Friedrich, Chief Engineer at Rosa. The poster compared several recently proposed model qualification approaches, including Rosa’s Model Qualification Method (MQM), to identify common themes and analyze differences. The symposium, entitled “Increasing Drug Development Success: Understanding Drug-Disease Interactions through Quantitative Systems Pharmacology”, was designed to bring together key global leaders in QSP to explore ways to leverage the interface of theoretical and experimental pharmacology to improve drug development efficiency. (press release)
Rosa & Co. LLC, today announced that Dr. Christina Friedrich, Chief Engineer, will lead a workshop at the QSP Congress Meeting on October 20th, 2015 in Boston, MA. The conference focuses on the uses and benefits of QSP in pharmaceutical drug development. Dr. Friedrich’s workshop is entitled ”Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach”. She will discuss the use of a systematic approach to model qualification, Rosa’s Model Qualification Method (MQM), which ensures that a model is developed and judged fit for use. Case studies and model examples will illustrate the MQM process. (press release)
Rosa & Co. LLC today announced it has five posters and a tutorial scheduled to be presented during the sixth American Conference on Pharmacometrics (ACoP6) in Crystal City, VA, October 4-7, 2015. The poster presentations will describe research and a range of results including the application of PhysioPD Platforms to clinical trial design and translational research. The posters will be presented with Sanofi, Bristol Myers Squibb, Stiefel, (a GSK company) and by Rosa & Co. The MathWorks, Inc. tutorial uses a Rheumatoid Arthritis PhysioPD Platform developed by Rosa to illustrate the use of SimBiology and MATLAB to streamline QSP workflows. (Press release)
Rosa & Co. LLC today announced a co-marketing agreement with MathWorks, developer of mathematical computing software and maker of MATLAB, SimBiology and Simulink. The agreement between MathWorks and Rosa will provide drug development professionals examples of how to address real world challenges using state-of-the-art software tools and proven QSP modeling approaches. (press release)
Rosa & Co. LLC today announced its pleasure to be a premier sponsor for the Discovery on Target Conference in Boston, MA on September 21-24th, 2015. The Quantitative Systems Pharmacology Tract at the conference is designed as a knowledge and opinion exchange forum, highlighting strategy and implementation of QSP from early discovery to early clinical development in the pharmaceutical industry. In addition to its sponsorship, Rosa will be presenting a talk and teaching a short course as part of the QSP program. (press release}
Rosa & Co. LLC is currentlly seeking a leader with a strong scientific background to support client business development activities. Reporting to the Senior Vice President of Scientific Alliances, the ideal candidate will partner with Clients Services on existing accounts and provide research and support for new account opportunities. (Announcement, pdf)
Rosa & Co. LLC, is pleased to announce the initiation of a multi-year Research Agreement with Sanofi Global R&D to provide Rosa’s market-leading PhysioPD services to worldwide Sanofi affiliates. The collaboration provides Sanofi a competitive research and development advantage and greater access to the extensive depth and breadth of Rosa’s expertise. Rosa’s agreement with Sanofi further extends Rosa’s presence as the global market leader in the Quantitative Systems Pharmacology field. (Press release)
Dr. Ananth Kadambi delivered the Keynote Address at the QSP Congress on April 28, 2015 in Basel, Switzerland. He discussed the philosophical and practical roles of QSP in the scientific process, common R&D applications, and key aspects of QSP market adoption. Additionally, on April 29, 2015, Dr. Mike Reed presented a significant case study that covered creating and performing research with PhysioPD™ Research Platforms. Rosa also participated in two panel discussions during the conference on current and future applications of QSP. (Press release)
Bristol-Myers Squibb and Rosa will present a poster describing a Virtual Systems Pharmacology (ViSP) web-based environment at the ASCPT 2015 Annual Meeting in New Orleans, LA. The poster, entitled “Virtual Systems Pharmacology (ViSP) flexible web-based environment for running large multi-scale models” will be presented by Tarek Leil, Ph.D. during the Quantitative Systems Pharmacology Pre-Conference Poster Session on Tuesday, March 3, 2015, 12:45 PM - 1:45 PM and during the Late-Breaking and Encore Poster Session I on Thursday, March 5th, 2015 from 4:30 – 6:30 PM at the Hyatt Regency, Elite Hall Foyer. (Abstract)(Press release)
Dr. Ananth Kadambi will be speaking at the 19th North American ISSX Meeting/29th JSSX Meeting at the Hilton, San Francisco, on Wednesday, October 22, 2014 at 9:00 - 11:30 a.m. His talk is entitled “Application of Quantitative System Pharmacology Modeling to Translational Research”.
Dr Christina Friedrich will be speaking at the American Conference on Pharmacometrics (ACoP) in Las Vegas NV, on Monday, October 13th at 3-5 pm. Her talk is entitled “Quantitative Systems Pharmacology (QSP) informs in vitro to in vivo translation for PCSK9 antibody”.
MedImmune and Rosa presented a poster, entitled "Quantitative Systems Pharmacology Modeling to Evaluate Clinical Response of an anti-TNFa/anti-Ang2 Bispecific Antibody in Rheumatoid Arthritis" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 20, 2014. The poster describes a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of rheumatoid arthritis, designed to address the target-mediated drug disposition kinetics of a bispecific antibody directed against TNFa and angiotensin 2. (Abstract)
Amgen and Rosa presented a poster, entitled "Pharmacology Model to Characterize the Effect of Blinatumomab in Patients With Adult B-Precursor Acute Lymphoblastic Leukemia" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 18 (Biologics pre-conference) and 21, 2014. The poster describes key questions addressed with a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of B-Precursor Acute Lymphoblastic Leukemia and the effect of blinatumomab, a T-cell activator that leads to B-cell death.
Rosa is pleased to announce the appointment of Ananth Kadambi, PhD, as Senior Vice President, PhysioPD, to manage their rapidly-expanding business in Japan and Asia. Dr. Kadami comes to Rosa from Evidera, where he served as as the Director of Modeling and Simulation. Previous to that, Dr. Kadambi rose from Team Leader to Vice President at Entelos Holdings, Inc. (Press release)
Rosa is pleased to announce the acquisition of the consulting service business of Entelos Holdings, Inc., which conducts mechanistic, physiologic, in silico modeling projects for customers in pharmaceutical research and development. The acquisition, which closed January 7, 2014, further extends Rosa’s presence in quantitative systems pharmacology and modeling and simulation research services and adds to Rosa's already significant expertise in cardiovascular, immunology, and metabolism biology, and human nutrition. (Press release)
Rosa is pleased to announce it has established an alliance with the KressWorks Foundation to develop a Ewing’s Sarcoma PhysioPD Research Platform, a quantitative model of the physiologic and pharmacologic mechanisms involved in Ewing’s Sarcoma. (Press release)